Iminoheterocycle as a druggable motif: BACE1 inhibitors and beyond

Trends in Pharmacological Sciences

Volumn 33, Issue 5, 2012, Pages 233-240

  Zhu, Zhaoning ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOPYRIDINE DERIVATIVE; ACETYLGLUCOSAMINIDASE; ACYLGUANIDINE DERIVATIVE; ALISKIREN; AMINOPYRIMIDINE DERIVATIVE; AMINOQUINOLINE DERIVATIVE; ASPARTIC PROTEINASE; BETA SECRETASE 1; BETA SECRETASE 1 INHIBITOR; BETA SECRETASE INHIBITOR; GLYCOSIDASE INHIBITOR; NITRIC OXIDE SYNTHASE INHIBITOR; OSELTAMIVIR; PROTEINASE INHIBITOR; PSEUDOTHIOUREA DERIVATIVE; RENIN INHIBITOR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG;

BINDING AFFINITY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 84860525249     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.02.003     Document Type: Review

References (34)

1. A. Patchett, and R.P. Nargund Privileged structures - an update Ann. Rep. Med. Chem. 35 2000 289 298
2. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 297 2002 353 356 (Pubitemid 34790756)
3. Evin, G. et al. (2011) BACE inhibitors as potential drugs for the treatment of Alzheimer's disease: focus on bioavailability. Recent Patents on CNS Drug Discovery 6, 91-106
4. A.K. Ghosh Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality Curr. Alzheimer Res. 4 2007 418 422 (Pubitemid 47416635)
5. I. Ulrich, and J.N. Cumming Peptidomimetic BACE1 inhibitors for treatment of Alzheimer's disease: design and evolution Methods Princ. Med. Chem. 45 2010 441 479
6. Y.-S. Wang Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel μM leads for the development of nM BACE-1 (β-site APP cleaving enzyme 1) inhibitors J. Med. Chem. 53 2010 942 950
7. D.C. Cole Acylguanidines as small-molecule β-secretase inhibitors J. Med. Chem. 49 2006 6158 6161
8. M. Congreve Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase J. Med. Chem. 50 2007 1124 1132 (Pubitemid 46496313)
9. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug. Del. Rev. 46 1996 3 26 (Pubitemid 33653411)
10. Z. Zhu Discovery of cyclic acylguanidines as highly potent and selective β-site amyloid cleaving enzyme (BACE) inhibitors: part I - inhibitor design and validation J. Med. Chem. 53 2010 951 965
11. J. Madden Fragment-based discovery and optimization of BACE1 inhibitors Bioorg. Med. Chem. Lett. 20 2010 5329 5333
12. M.S. Malamas Novel pyrrolyl 2-aminopyridines as potent and selective human β-secretase (BACE1) inhibitors Bioorg. Med. Chem. Lett. 20 2010 2068 2073
13. S. Geschwindner Discovery of a novel warhead against β-secretase through fragment-based lead generation J. Med. Chem. 50 2007 5903 5911
14. P.D. Edwards Application of fragment-based lead generation to the discovery of novel, cyclic amidine β-secretase inhibitors with nanomolar potency, cellular activity, and high ligand J. Med. Chem. 50 2007 5912 5925
15. 1 substrate binding pocket Bioorg. Med. Chem. Lett. 18 2008 767 771
16. W.F. Fobare Thiophene substituted acylguanidines as BACE1 inhibitors Bioorg. Med. Chem. Lett. 17 2007 5353 5356 (Pubitemid 47391283)
17. D.C. Cole Acylguanidine inhibitors of β-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets Bioorg. Med. Chem. Lett. 18 2008 1063 1066 (Pubitemid 351179339)
18. M.S. Malamas Design and synthesis of 5,5′-disubstituted aminohydantoins as potent and selective human β-secretase (BACE1) inhibitors J. Med. Chem. 53 2010 1146 1158
19. P. Nowak Discovery and initial optimization of 5,5-disubstituted aminohydantoins as potent β-secretase (BACE1) inhibitors Bioorg. Med. Chem. Lett. 20 2010 632 635
20. A.K. Ghosh, and B.D. Chapsal Second-generation approved HIV protease inhibitors for the treatment of HIV/AIDS Methods Princ. Med. Chem. 45 2010 169 204
21. J. Rahuel Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human rennin Chem. Biol. 7 2010 493 504
22. I. Russo Plasmepsin V licenses Plasmodium proteins for export into the host erythrocyte Nature 463 2010 632 636
23. M. Sinnott Catalytic mechanisms of enzymic glycosyl transfer Chem. Rev. 90 1990 1171 1202
24. S.A. Yuzwa A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo Nat. Chem. Biol. 4 2008 483 490
25. R.J. Copeland Cross-talk between GlcNAcyclation and phosphorylation: roles in insulin resistance and glucose toxicity Am. J. Physiol. Endocrinol Metab. 295 2008 17 28
26. C.S. Rye, and S.G. Wither Glycosidase mechanisms Curr. Opin. Chem. Biol. 4 2000 573 580
27. D.E. Koshland Jr. Stereochemistry and the mechanism of enzymic reactions Biol. Rev. 28 1953 416 436
28. T. Kajimoto, and M. Node Synthesis of glycosyltransferase inhibitors glycosyltransferase Synthesis 19 2009 3179 3210
29. R. Brenk Crystallographic study of inhibitors of tRNA-guanine transglycosylase suggests a new structure-based pharmacophore for virtual screening J. Mol. Biol. 338 2004 55 75 (Pubitemid 38429786)
30. S.R. Hortner Potent inhibitors of tRNA-guanine transglycosylase, an enzyme linked to the pathogenicity of the Shigella bacterium: charge-assisted hydrogen bonding Angew. Chem. Int. Ed. 46 2007 8266 8269 (Pubitemid 350096614)
31. D.C. Cole Identification and characterization of acidic mammalian chitinase inhibitors J. Med. Chem. 53 2010 6122 6128
32. C.L. Rush Natural product - guided discovery of a fungal chitinase inhibitor Chem. Biol. 17 2010 1275 1281
33. A.W.E. Chan Chemical fragments that hydrogen bond to Asp, Glu, Arg, and his side chains in protein binding sites J. Med. Chem. 53 2010 3086 3094
34. F. Xue Potent, highly selective, and orally bioavailable gem-difluorinated monocationic inhibitors of neuronal nitric oxide synthase J. Am. Chem. Soc. 132 2010 14229 14238